Illumina, Inc. (NASDAQ:ILMN) Holdings Trimmed by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 143,048 shares of the life sciences company’s stock after selling 11,533 shares during the period. Exchange Traded Concepts LLC’s holdings in Illumina were worth $19,116,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. D.B. Root & Company LLC purchased a new stake in Illumina in the 4th quarter worth about $204,000. Janney Montgomery Scott LLC lifted its position in shares of Illumina by 32.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 8,710 shares of the life sciences company’s stock worth $1,164,000 after purchasing an additional 2,130 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Illumina by 14.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 24,396 shares of the life sciences company’s stock worth $3,260,000 after purchasing an additional 3,102 shares in the last quarter. Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in shares of Illumina by 116.7% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 13,000 shares of the life sciences company’s stock worth $1,737,000 after purchasing an additional 7,000 shares during the period. Finally, Ballentine Partners LLC purchased a new position in Illumina during the fourth quarter valued at approximately $268,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $136.26 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock’s 50 day moving average price is $139.06 and its two-hundred day moving average price is $134.26. The firm has a market capitalization of $21.61 billion, a P/E ratio of -13.63 and a beta of 1.11. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the company posted $0.33 earnings per share. On average, equities analysts forecast that Illumina, Inc. will post 4.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ILMN. Piper Sandler decreased their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Morgan Stanley lowered their target price on Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Royal Bank of Canada raised their price target on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. TD Cowen boosted their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.